BIOTRONIK Announces Compelling Program of Clinically and Scientifically Significant Presentations at European Society of Cardiology Congress 2011

B/BIOTRONIK_0

BIOTRONIK Announces Compelling Program of Clinically and Scientifically Significant Presentations at European Society of Cardiology Congress 2011

2011-08-26 17:29

Health and Pharmaceutical

Several studies to be highlighted including a collective total of more than 4,000 randomized patients

BERLIN--(BUSINESS WIRE)--BIOTRONIK, a leading manufacturer of implantable cardiac devices and the pioneer of wireless remote monitoring technology, announced today that several important clinical studies sponsored by BIOTRONIK will be presented at the European Society of Cardiology (ESC) Congress 2011 to be held in Paris, France, from August 27-31. The ESC Congress is a world premier conference on the science, management, and prevention of cardiovascular disease.

Major highlights include two oral presentations on the ECOST trial (Effectiveness and Cost of ICD Follow-Up Schedule with Telecardiology) during the Hot Line II and Meet-the-Trialist III sessions on Monday, August 29. ECOST investigates the safety, effectiveness, and costs of long-term follow-up over 27 months with BIOTRONIK Home Monitoring^®in ICD patients. In the Hot Line Session, Principal Investigator Professor Salem Kacet will present the results from ECOST, which will then be discussed by Professor Jean-Claude Daubert. The high-profile Hot Line Sessions are reserved for first-time presentation of the primary endpoints of recently completed trials-and will also be available as webcasts on the ESC Congress website. In the Meet-the-Trialist Session, participants have the opportunity to interact directly with Professor Kacet and delve into further details on ECOST. The prestigious and highly Meet the Trialist Sessions cover five of the best late-breaking trials from the Hot Line Sessions.

Additionally, Dr. Niraj Varma, Principal Investigator of TRUST, will present new data from the landmark TRUST trial (Lumax-T/Lumos-T Safely Reduces Routine Office Device Follow-up), which demonstrated the safety and effectiveness of remote follow-up of ICD patients with BIOTRONIK Home Monitoring^®. This new data will show event detection in high-risk ICD patients with BIOTRONIK Home Monitoring^® on Sunday, August 28. On the following day, Dr. Varma will present new findings on how well this technology reduces the burden of unnecessary hospital visits.

Furthermore, new findings from the unique industry-wide REPLACE registry (Implantable Cardiac Pulse Generator Replacement), which provides a comprehensive risk quantification of pacemaker and ICD replacement and upgrade, will be presented on Sunday, August 28. REPLACE Principal Investigator Dr. Jeanne Poole will show data on the time-course of complications following pacemaker or ICD replacement, and Investigator Dr. Behzad Pavri will share insights on the likeliness of upgrade to CRT in pacemaker versus ICD patients.

Finally, two more presentations of studies with BIOTRONIK Home Monitoring^® will add further substantiation to the significant body of evidence already existing for this advanced technology: Dr. Renato Pietro Ricci will show preliminary results from the HomeGuide Registry on the manpower as well as sensitivity and positive predictive value of adverse event detection with BIOTRONIK Home Monitoring^®. Dr. Ermenegildo de Ruvo will share insights on the long-term risk reduction of misdetection or delayed detection of adverse events with BIOTRONIK Home Monitoring^® in CRT-D patients.

"At BIOTRONIK, we are committed to setting new standards in clinical excellence," commented Marlou Janssen, Global Vice President of Marketing and Sales. "Our clinical professionals worldwide collaborate closely with top scientific experts at universities, research institutes, and in the medical community to develop and study highly reliable and innovative products that help physicians save and improve patients' lives."

"Our commitment to clinical excellence will be demonstrated this year at the ESC Congress 2011, via a considerable number of significant presentations that examine the clinical experience with a collective total of more than 5,000 patients," stated Janssen.

About ESC Congress

The ESC Congress, the largest medical meeting in Europe, is organized by the European Society of Cardiology, which represents 68,000 cardiology professionals across Europe and the Mediterranean, provides an array of scientific and educational activities, and edits and publishes seven of the world's leading journals on cardiology. For more information about ESC Congress 2011, visit www.escardio.org.

About BIOTRONIK SE & Co. KG

As one of the world's leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of over 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.

More information: www.biotronik.com

Upon publication, please provide us with a copy.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6841017&lang=en